2,194 Shares in GE HealthCare Technologies Inc. (NASDAQ:GEHC) Purchased by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC bought a new stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) in the third quarter, Holdings Channel reports. The fund bought 2,194 shares of the company’s stock, valued at approximately $206,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. ORG Partners LLC increased its position in GE HealthCare Technologies by 2,475.0% during the 2nd quarter. ORG Partners LLC now owns 412 shares of the company’s stock valued at $32,000 after buying an additional 396 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of GE HealthCare Technologies by 8.3% during the second quarter. Assenagon Asset Management S.A. now owns 12,479 shares of the company’s stock valued at $972,000 after acquiring an additional 953 shares in the last quarter. Blue Trust Inc. raised its position in shares of GE HealthCare Technologies by 16.9% in the 2nd quarter. Blue Trust Inc. now owns 2,124 shares of the company’s stock worth $166,000 after purchasing an additional 307 shares during the last quarter. TCW Group Inc. raised its position in shares of GE HealthCare Technologies by 33.6% in the 2nd quarter. TCW Group Inc. now owns 499,415 shares of the company’s stock worth $38,914,000 after purchasing an additional 125,612 shares during the last quarter. Finally, Raymond James & Associates boosted its stake in GE HealthCare Technologies by 10.4% in the 2nd quarter. Raymond James & Associates now owns 381,702 shares of the company’s stock worth $29,742,000 after purchasing an additional 36,076 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Trading Down 1.4 %

Shares of NASDAQ:GEHC opened at $81.63 on Friday. GE HealthCare Technologies Inc. has a 12-month low of $71.31 and a 12-month high of $94.55. The company has a market cap of $37.29 billion, a PE ratio of 22.43, a price-to-earnings-growth ratio of 2.96 and a beta of 1.07. The stock has a 50 day moving average of $86.04 and a 200 day moving average of $83.70. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12.

GE HealthCare Technologies (NASDAQ:GEHC) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.06 by $0.08. The business had revenue of $4.86 billion during the quarter, compared to analyst estimates of $4.87 billion. GE HealthCare Technologies had a net margin of 8.56% and a return on equity of 25.19%. The company’s revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business posted $0.99 earnings per share. As a group, equities research analysts expect that GE HealthCare Technologies Inc. will post 4.3 EPS for the current year.

GE HealthCare Technologies Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Tuesday, January 14th will be paid a $0.035 dividend. This represents a $0.14 dividend on an annualized basis and a yield of 0.17%. The ex-dividend date of this dividend is Tuesday, January 14th. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. GE HealthCare Technologies’s dividend payout ratio is presently 3.30%.

Insider Buying and Selling at GE HealthCare Technologies

In other GE HealthCare Technologies news, CEO Roland Rott sold 3,577 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total value of $309,338.96. Following the completion of the transaction, the chief executive officer now directly owns 24,298 shares in the company, valued at $2,101,291.04. This represents a 12.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on GEHC shares. Evercore ISI boosted their target price on GE HealthCare Technologies from $98.00 to $102.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Stifel Nicolaus increased their price objective on shares of GE HealthCare Technologies from $100.00 to $102.00 and gave the company a “buy” rating in a research report on Monday, September 30th. JPMorgan Chase & Co. started coverage on shares of GE HealthCare Technologies in a research report on Monday, September 9th. They issued a “neutral” rating and a $90.00 target price for the company. BTIG Research raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Wednesday, September 18th. Finally, UBS Group lowered GE HealthCare Technologies from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $84.00 to $74.00 in a report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $95.46.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.